89 related articles for article (PubMed ID: 14726715)
1. Paroxetine and the FDA.
Connor DF
J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):127. PubMed ID: 14726715
[No Abstract] [Full Text] [Related]
2. Paroxetine and the FDA.
Riddle MA
J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):128-30. PubMed ID: 14964296
[No Abstract] [Full Text] [Related]
3. Paroxetine and the FDA.
Brent DA
J Am Acad Child Adolesc Psychiatry; 2004 Feb; 43(2):127-8. PubMed ID: 14971062
[No Abstract] [Full Text] [Related]
4. British panel bans use of antidepressant to treat children.
Abbott A
Nature; 2003 Jun; 423(6942):792. PubMed ID: 12815392
[No Abstract] [Full Text] [Related]
5. Effects of Food and Drug Administration warnings on antidepressant use in a national sample.
Olfson M; Marcus SC; Druss BG
Arch Gen Psychiatry; 2008 Jan; 65(1):94-101. PubMed ID: 18180433
[TBL] [Abstract][Full Text] [Related]
6. Paxil and self-scratching.
Weintrob A
J Am Acad Child Adolesc Psychiatry; 2001 Jan; 40(1):5. PubMed ID: 11195562
[No Abstract] [Full Text] [Related]
7. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine.
Greist J; McNamara RK; Mallinckrodt CH; Rayamajhi JN; Raskin J
Clin Ther; 2004 Sep; 26(9):1446-55. PubMed ID: 15531007
[TBL] [Abstract][Full Text] [Related]
8. FDA alert on antidepressants for youth.
Mitka M
JAMA; 2003 Nov; 290(19):2534. PubMed ID: 14625316
[No Abstract] [Full Text] [Related]
9. Does the FDA proposed list of possible correlates of suicidality associated with antidepressants apply to an adult private practice population?
Akiskal HS; Benazzi F
J Affect Disord; 2006 Aug; 94(1-3):105-10. PubMed ID: 16766043
[TBL] [Abstract][Full Text] [Related]
10. Teen suicide pills? An FDA panel calls for tough labels on antidepressants. What it means for you.
Gorman C
Time; 2004 Sep; 164(13):77. PubMed ID: 15478737
[No Abstract] [Full Text] [Related]
11. An historical note on suicide during the course of treatment for depression.
Goldney RD
Suicide Life Threat Behav; 2007 Feb; 37(1):116-7. PubMed ID: 17397286
[No Abstract] [Full Text] [Related]
12. Psychopharmacology. Study questions antidepressant risks.
Couzin J
Science; 2007 Apr; 316(5823):354. PubMed ID: 17446361
[No Abstract] [Full Text] [Related]
13. Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States.
Nemeroff CB; Kalali A; Keller MB; Charney DS; Lenderts SE; Cascade EF; Stephenson H; Schatzberg AF
Arch Gen Psychiatry; 2007 Apr; 64(4):466-72. PubMed ID: 17404123
[TBL] [Abstract][Full Text] [Related]
14. Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil.
Lee P; Shu L; Xu X; Wang CY; Lee MS; Liu CY; Hong JP; Ruschel S; Raskin J; Colman SA; Harrison GA
Psychiatry Clin Neurosci; 2007 Jun; 61(3):295-307. PubMed ID: 17472599
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant use in children.
FDA Consum; 2004; 38(1):3. PubMed ID: 15032181
[No Abstract] [Full Text] [Related]
16. SSRIs associated with behavioral activation and suicidal ideation.
Vorstman J; Lahuis B; Buitelaar JK
J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1364-5. PubMed ID: 11765279
[No Abstract] [Full Text] [Related]
17. Congress investigates FDA's handling of antidepressant safety information.
Young D
Am J Health Syst Pharm; 2004 Nov; 61(21):2228, 2230, 2232 passim. PubMed ID: 15552624
[No Abstract] [Full Text] [Related]
18. Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder".
Hashimoto K
J Clin Psychopharmacol; 2009 Aug; 29(4):411-2; author reply 412. PubMed ID: 19593196
[No Abstract] [Full Text] [Related]
19. FDA again reviews antidepressants.
Tanne JH
BMJ; 2004 Aug; 329(7464):475. PubMed ID: 15331461
[No Abstract] [Full Text] [Related]
20. Restless legs syndrome associated with the combined use of duloxetine plus paroxetine.
Nikolaou KN; Michopoulos I; Douzenis A; Papazahos C; Papageorgiou C; Gournellis R
J Clin Psychopharmacol; 2015 Jun; 35(3):345-6. PubMed ID: 25815756
[No Abstract] [Full Text] [Related]
[Next] [New Search]
